111 (NASDAQ:YI – Get Free Report) and Fulgent Genetics (NASDAQ:FLGT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Insider & Institutional Ownership
21.3% of 111 shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 43.9% of 111 shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
111 has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 111 | 1 | 0 | 0 | 0 | 1.00 |
| Fulgent Genetics | 1 | 2 | 1 | 0 | 2.00 |
Fulgent Genetics has a consensus price target of $27.50, suggesting a potential upside of 33.17%. Given Fulgent Genetics’ stronger consensus rating and higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than 111.
Profitability
This table compares 111 and Fulgent Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 111 | -0.76% | N/A | -3.80% |
| Fulgent Genetics | -26.05% | -4.93% | -4.50% |
Valuation & Earnings
This table compares 111 and Fulgent Genetics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 111 | $1.80 billion | 0.02 | -$9.65 million | ($1.40) | -2.38 |
| Fulgent Genetics | $322.67 million | 1.76 | -$60.51 million | ($2.82) | -7.32 |
111 has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than 111, indicating that it is currently the more affordable of the two stocks.
Summary
111 beats Fulgent Genetics on 8 of the 14 factors compared between the two stocks.
About 111
111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
